Digital therapeutics market seen topping $37.6 billion by 2030
The Business Research Company projects the digital therapeutics market will grow at a 28% annual rate through 2030, driven by chronic disease management, telehealth adoption and wider smartphone access. North America and the U.S. are expected to lead the category, while software remains the biggest product segment.
Why it matters: - Digital therapeutics are moving from a niche category into a larger part of digital health, with projected revenue topping $37.61 billion by 2030. - The market’s growth reflects demand for scalable, evidence-based tools that can support chronic disease management outside traditional clinical settings. - The category is still small relative to the broader healthcare market, but its rapid growth suggests stronger adoption by providers, employers and patients.
What happened: - The Business Research Company said the digital therapeutics market is forecast to grow at a 28% compound annual growth rate through 2030. - The company projected North America will lead the market in 2030 with a value of $19 billion, up from $6 billion in 2025. - The U.S. is projected to be the largest single-country market, reaching $13 billion in 2030 from $4 billion in 2025. - Software is expected to be the biggest product segment in 2030, representing 64% of the market, or about $24 billion. - The market is segmented by sales channel into business-to-business and business-to-consumer, and by application into preventive care and treatment-related use cases. - The report is titled The Business Research Company’s Digital Therapeutics Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report includes a free sample and full report access through the company’s website: Request a free sample and Access the detailed report.
The details: - The report puts digital therapeutics at more than 6% of the projected $662 billion digital health market by 2030. - The category would represent nearly 0.3% of the projected $11.335 trillion healthcare services market. - North America’s growth is linked to prescription digital therapeutics, integration with electronic health records, reimbursement support and rising chronic disease rates. - U.S. growth is tied to FDA-approved digital therapeutics, employer adoption, smartphone use, partnerships with pharmaceutical companies and patient preference for software-based disease management. - The software segment’s growth is supported by AI-driven applications, cloud platforms, continuous remote updates and clinical evidence of improved adherence and long-term outcomes. - The software and devices segments together are projected to exceed $27 billion by 2030. - Between 2025 and 2030, the software segment is expected to add $17 billion, while the devices segment is expected to add $10 billion. - The market is being shaped by rising chronic disease prevalence, including diabetes, cardiovascular disease, respiratory disorders and mental health conditions. - Remote healthcare adoption is boosting demand for digital therapeutics through telehealth pathways, virtual engagement and home-based care. - Wider smartphone and internet access is expanding use of mobile therapeutic programs and remote communication with clinicians. - The company estimates chronic disease management will add about 2.4% annual growth, remote healthcare models about 2.2%, and smartphones and internet connectivity about 2.0%. - Teladoc Health Inc. led global digital therapeutics sales in 2025 with a 3% market share. - Teladoc Health’s portfolio includes AI-driven chronic care management, virtual behavioral health, diabetes and hypertension management, and personalized digital treatment programs. - The market is fragmented, with the top 10 companies accounting for just 6% of revenue in 2025. - The company named a long list of major participants, including Omada Health, Medtronic, Virta Health, Noom Health, Propeller Health, DarioHealth, WellDoc, Biofourmis and Pear Therapeutics. - The report also lists technology suppliers such as Microsoft, Amazon Web Services, Google Cloud, Oracle, SAP, Salesforce, NVIDIA, Qualcomm, Intel, Arm, Synopsys, Red Hat, MongoDB, Snowflake, Twilio, Cloudflare, Okta and Datadog. - Distribution channels include IQVIA, Ingram Micro, TD SYNNEX, Carahsoft, SHI, CDW, Insight Enterprises, Softchoice, Arrow Electronics, Tech Data, Cardinal Health, McKesson, Cencora, Henry Schein, EMIS Group, Xealth, Redox and Innovaccer. - End users include Mayo Clinic, Cleveland Clinic, Kaiser Permanente, HCA Healthcare, Ascension Health, CommonSpirit Health, Mass General Brigham, Intermountain Health, Veterans Health Administration, the National Health Service, CVS Health, UnitedHealth Group, Cigna, Humana, Aetna, Blue Cross Blue Shield Association, Apollo Hospitals, Fortis Healthcare and Ramsay Health Care.
Between the lines: - The market is still early in its maturity, and the top 10 players’ 6% revenue share suggests no company has yet established broad control. - The focus on interoperability, reimbursement and clinical validation shows that commercial success will depend on more than software features. - The category’s growth is being driven by healthcare system pressure to manage chronic disease more efficiently and at lower cost. - A June 2026 collaboration between Welldoc and Senseonics shows how companies are using partnerships to build more connected care tools. - The collaboration is designed to create a mobile app for the Eversense 365 continuous glucose monitoring system and integrate AI-driven health management, metabolic tracking and improved user experience. - The app is also expected to support interoperability with Apple Health and Google Health Connect.
What's next: - The market’s next stage will likely center on clinical validation, regulatory approvals and broader reimbursement coverage. - Companies are expected to keep expanding AI-powered personalized therapeutics, remote monitoring and chronic disease offerings. - Partnerships between digital therapeutics developers, device makers and healthcare platforms are likely to remain a key route to scale. - Further growth will depend on whether digital therapeutics can prove consistent outcomes and integrate smoothly into existing care workflows.
The bottom line: - Digital therapeutics are becoming a meaningful growth segment in healthcare, but the market’s next leg of expansion will depend on reimbursement, evidence and interoperability as much as on demand.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Essential Healthcare News
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.